Department of Neurology, Klinikum Grosshadern of the Ludwig Maximilians University.
Department of Clinical Microbiology, Copenhagen University Hospital Hvidovre, Denmark.
J Infect Dis. 2015 Jul 15;212(2):247-57. doi: 10.1093/infdis/jiv028. Epub 2015 Jan 20.
Neutrophilic inflammation often persists for days despite effective antibiotic treatment and contributes to brain damage in bacterial meningitis. We propose here that myeloid-related protein 14 (MRP14), an abundant cytosolic protein in myeloid cells, acts as an endogenous danger signal, driving inflammation and aggravating tissue injury.
The release pattern of MRP14 was analyzed in human and murine cerebrospinal fluid (CSF), as well as in isolated neutrophils. Its functional role was assessed in a mouse meningitis model, using MRP14-deficient mice.
We detected large quantities of MRP14 in CSF specimens from patients and mice with pneumococcal meningitis. Immunohistochemical analyses and a cell-depletion approach indicated neutrophils as the major source of MRP14. In a meningitis model, MRP14-deficient mice showed a better resolution of inflammation during antibiotic therapy, which was accompanied by reduced disease severity. Intrathecal administration of MRP14 before infection reverted the phenotype of MRP14-deficient mice back to wild type. Moreover, intrathecal injection of MRP14 alone was sufficient to induce meningitis in a Toll-like receptor 4 (TLR4)-CXCL2-dependent manner. Finally, treatment with the MRP14 antagonist paquinimod reduced inflammation and disease severity significantly, reaching levels comparable to those achieved after genetic depletion of MRP14.
The present study implicates MRP14 as an essential propagator of inflammation and potential therapeutic target in pneumococcal meningitis.
尽管抗生素治疗有效,但中性粒细胞炎症通常会持续数天,并导致细菌性脑膜炎的脑损伤。我们在此提出,髓系相关蛋白 14(MRP14)是髓系细胞中丰富的细胞溶质蛋白,作为一种内源性危险信号,驱动炎症并加重组织损伤。
分析了人及鼠脑脊液(CSF)中以及分离的中性粒细胞中 MRP14 的释放模式。使用 MRP14 缺陷型小鼠评估了其在小鼠脑膜炎模型中的功能作用。
我们在患有肺炎球菌性脑膜炎的患者和小鼠的 CSF 标本中检测到大量的 MRP14。免疫组织化学分析和细胞耗竭方法表明,中性粒细胞是 MRP14 的主要来源。在脑膜炎模型中,MRP14 缺陷型小鼠在抗生素治疗期间表现出更好的炎症消退,同时疾病严重程度降低。在感染前鞘内给予 MRP14 可使 MRP14 缺陷型小鼠的表型恢复为野生型。此外,单独鞘内注射 MRP14 即可通过 Toll 样受体 4(TLR4)-CXCL2 依赖方式诱导脑膜炎。最后,MRP14 拮抗剂帕奎莫德的治疗可显著减轻炎症和疾病严重程度,达到与遗传耗尽 MRP14 后相当的水平。
本研究提示 MRP14 是炎症的重要传播者,也是肺炎球菌性脑膜炎的潜在治疗靶点。